- Evonik and Ethris collaborate on a lipid nanoparticle platform for nucleic acid delivery.
- Ethris' SNaP LNP technology enhances stability and targeting for mRNA therapies.
- The LNP market is projected to reach $2.3 billion by 2032.
- Evonik expands its nucleic acid medicine solutions through strategic partnerships.
Partnership Overview
Evonik and Ethris have formed a strategic collaboration to develop a novel lipid nanoparticle (LNP) platform for nucleic acid delivery. This partnership aims to enhance the stability and targeting of nucleic acid therapies and vaccines.
Technological Advancements
Ethris' proprietary SNaP LNP technology offers improved thermostability and local retention, facilitating targeted delivery and prolonged presence at the site of action. This technology supports new therapeutic formats, such as nebulized delivery for respiratory diseases, and minimizes off-target effects.
Market Potential
The LNP market is expected to grow significantly, reaching an estimated $2.3 billion by 2032. This growth is driven by the increasing demand for scalable, high-quality nucleic acid technologies.
Strategic Goals
Evonik aims to expand its portfolio of system solutions for nucleic acid medicines through strategic partnerships. This collaboration with Ethris aligns with Evonik's focus on advanced precision biosolutions, leveraging biotechnology to enhance human health and quality of life.
